Phase II Clinical Trial of Camrelizumab Combined With AVD (Epirubicin, Vincristine and Dacarbazine) in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma

Who is this study for? Adult patients with Hodgkin's Lymphoma
What treatments are being studied? Camrelizumab
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This is a prospective phase II clinical trial to observe the efficacy and safety of Camrelizumab combined with AVD in the first-line treatment for patients with advanced classical Hodgkin's lymphoma.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

• Age between 18 to 75 years old (including 18 and 75)

• Diagnosed as advanced classical hodgkin's lymphoma based on histopathology

• Subjects must be untreated (Ann Arbor Stage III/IV or Ann Arbor II with B symptoms along with mediastinal big tumor or extranodal changes)

• No receiving chemotherapy before enrollment

• Having at least one measurable lesions

• World health organization-Eastern Cooperative Oncology Group Performance Status (ECOG) 0-2

• Life expectancy no less than 3 months

• enough main organ function

• Pregnancy test within 7 days must be negative for women of childbearing period, and appropriate measures should be taken for contraception for women in childbearing period during the study and six months after this study

⁃ Agreeing to sign the written informed consents

Locations
Other Locations
China
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university
RECRUITING
Zhengzhou
Contact Information
Primary
Yanyan Liu, M.D. Ph.D
yyliu@zzu.edu.cn
+8613818176375
Time Frame
Start Date: 2019-08-26
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 60
Treatments
Experimental: Camrelizumab Combined With AVD regimen
Camrelizumab 200mg, Intravenous administration on day 1 and day 15 combined with regimen:AVD (Epirubicin, Vincristine and Dacarbazine): repeated every 4 weeks, up to 6 cycles.
Sponsors
Leads: Henan Cancer Hospital

This content was sourced from clinicaltrials.gov

Similar Clinical Trials